BRAF and neoplasm: In Figure 4, the samples within each of these two tumor groups are organized horizontally in order from low to high phosphopeptide levels, to visualize the higher percentage of KRAS/BRAF wild-type tumors that produced higher than mean phosphorylation levels for the 11 substrates (18 of 36 samples) than tumors with mutated KRAS/BRAF performing correspondingly (6 of 27 samples; P = 0.036).